Market closed
Delcath Systems/$DCTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Delcath Systems
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Ticker
$DCTH
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
96
Website
Delcath Systems Metrics
BasicAdvanced
$402M
-
-$0.93
0.85
-
Price and volume
Market cap
$402M
Beta
0.85
52-week high
$16.97
52-week low
$5.15
Average daily volume
451K
Financial strength
Current ratio
12.005
Quick ratio
10.457
Long term debt to equity
1.357
Total debt to equity
1.51
Management effectiveness
Return on assets (TTM)
-13.47%
Return on equity (TTM)
-58.59%
Valuation
Price to revenue (TTM)
9.227
Price to book
5.79
Price to tangible book (TTM)
5.79
Price to free cash flow (TTM)
-17.842
Growth
Revenue change (TTM)
1,701.69%
Earnings per share change (TTM)
-68.50%
3-year revenue growth (CAGR)
118.74%
3-year earnings per share growth (CAGR)
-36.35%
What the Analysts think about Delcath Systems
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Delcath Systems stock.
Delcath Systems Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Delcath Systems Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Delcath Systems News
AllArticlesVideos
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Business Wire·3 days ago
Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma
Business Wire·3 weeks ago
Hospitals Experience FOMO In Adopting Delcath's PHP Treatment
Seeking Alpha·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Delcath Systems stock?
Delcath Systems (DCTH) has a market cap of $402M as of May 02, 2025.
What is the P/E ratio for Delcath Systems stock?
The price to earnings (P/E) ratio for Delcath Systems (DCTH) stock is 0 as of May 02, 2025.
Does Delcath Systems stock pay dividends?
No, Delcath Systems (DCTH) stock does not pay dividends to its shareholders as of May 02, 2025.
When is the next Delcath Systems dividend payment date?
Delcath Systems (DCTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Delcath Systems?
Delcath Systems (DCTH) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.